Lung adenocarcinoma that spread to the thyroid 9 years later

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: thyroid

After the thyroid metastasis was removed, she started systemic chemotherapy and remained under oncology management.

PubMed CentralRead more →

Stage III Inflammatory Breast Cancer: Rhonda's Patient Story

Patient Info: Rhonda Holbert, Female | Stage III

Rhonda survived inflammatory breast cancer and later lived with significant long-term health effects while continuing to support and advocate for other people with cancer.

Invasive Ductal Carcinoma: Shelby's Patient Story

Patient Info: Shelby, Female, Under 40

As of June 2026, Shelby had undergone double mastectomy and AC chemotherapy during pregnancy as a surrogate and delivered a healthy baby; long-term cancer status was not clearly stated.

The Patient StoryRead more →

Ovarian Cancer: Robyn's Survivor Story

Patient Info: Robyn Townsend

After surgery, 6 rounds of chemotherapy and ongoing olaparib, she reported no evidence of disease since the previous December.

MD AndersonRead more →

Colorectal Cancer: Monica's Survivor Story

Patient Info: Monica Diaz

Monica reported no evidence of disease since March 17, 2025, while continuing to recover physically and emotionally.

Fight Colorectal CancerRead more →

Stage IV Breast Cancer: Betty's Patient Story

Patient Info: Betty Jean, Female | Stage IV

Metastatic Site: Spine; ribs; liver

As of June 2026, Betty Jean was living with Stage IV metastatic breast cancer after bone involvement in the spine/ribs and later progression to the liver, with treatment including targeted therapy, radiation, and chemotherapy.

The Patient StoryRead more →

Rectal Cancer Treatment Complicated by a New Bleeding Disorder

Patient Info: Anonymized, female, 60s

The rectal cancer entered complete remission after surgery and 6 cycles of adjuvant chemotherapy.

PubMed CentralRead more →

Long-term lung cancer response complicated by immune-related lung inflammation

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: KRAS mutation; PD-L1 90%

Metastatic Site: pleura|lungs|peritoneum|bone|brain

By October 2025, the lung inflammation had resolved and she remained in systemic and intracranial remission.

PubMed CentralRead more →

HER2-mutated lung cancer: restarting targeted therapy after lung inflammation

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HER2 exon 20 insertion; PD-L1 negative

Metastatic Site: brain

Trastuzumab deruxtecan was restarted successfully after lung inflammation improved, but it was discontinued after 9 cycles when the cancer progressed.

PubMed CentralRead more →

Stage III Colorectal Cancer: Zed's Survivor Story

Patient Info: Zed, Male, Under 40 | Stage III

Biomarkers: Lynch syndrome

As of June 2026, Zed had completed colectomy and chemotherapy and was in surveillance with no evidence of disease. Lynch syndrome was also identified, supporting stricter long-term surveillance.

The Patient StoryRead more →

Stage IV lung cancer presenting with a paraneoplastic neurologic syndrome and mixed tumor features

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: PD-L1 0%

Metastatic Site: bone (T10 and L5 vertebrae)

He died after rapid deterioration with severe encephalopathy, weakness and respiratory distress; advanced metastatic lung cancer with progressive paraneoplastic neurologic involvement was considered the most likely cause.

PubMed CentralRead more →

Stage IV Colorectal Adenocarcinoma: Adrienne's Patient Story

Patient Info: Adrienne, Female | Stage IV

Metastatic Site: Liver

As of June 2026, Adrienne had Stage IV colon adenocarcinoma with liver metastases, had experienced liver recurrence after intensive multimodal treatment, and was back on FOLFIRI plus Avastin.

The Patient StoryRead more →

Stable lung cancer after recovery from a severe immunotherapy complication

Patient Info: Anonymized, Male, 60s

At 8-month follow-up, the primary lung tumor remained radiologically stable on maintenance chemotherapy without evidence of progression.

PubMed CentralRead more →

Stage III Colorectal Cancer: Laura's Survivor Story

Patient Info: Laura Behnke, Female | Stage III

As of June 2026, Laura reported no trace of rectal cancer after treatment, ileostomy reversal, and port removal, while continuing to manage bowel-function changes and survivorship effects.

The Patient StoryRead more →

Leukemia: Nicole's Survivor Story

Patient Info: Nicole Schulz, Female, Under 40

Nicole remained in remission after AML treatment and 2 bone marrow transplants, later had early squamous cell carcinoma addressed quickly, and continued long-term survivorship care for treatment effects and late-risk monitoring.

City of HopeRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: clonal evolution, chemoimmunotherapy response, osimertinib rechallenge, and death after progression

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Markers changed over time: started with EGFR L747S/L858R; later MET-amplified, PD-L1 TPS 80%, high TMB clone; later EGFR reappeared.

Metastatic Site: pleura, peritoneal nodule, retroperitoneal lymph nodes

The patient died on 30 April 2025 after progression through multiple lines and infection related to treatment-associated myelosuppression.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Shannon's Survivor Story

Patient Info: Shannon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: cervical spine (C1/C2 and C4/C6), liver

As of June 2026, Shannon described no evidence of active disease: visible tumors were gone, the original lung mass had decreased from 10.8 cm to a 3.8 cm cavity, and targeted therapy continued to suppress possible remaining cells.

The Patient StoryRead more →

Long-term complete response to targeted therapy for relapsed lung cancer with an EGFR mutation

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: EGFR mutation

Her three most recent scans showed a complete response, and nearly 4 years after relapse she remained free of tumor progression while continuing targeted therapy.

PubMed CentralRead more →

Stage IIA triple-negative neuroendocrine breast carcinoma with chemoimmunotherapy response

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Triple-negative neuroendocrine breast carcinoma with PD-L1 CPS >=10, and reported germline BRCA1/2 mutation.

As of March 2025, 12 months after surgery, follow-up imaging and tumor-marker testing showed no local recurrence or distant metastasis, and she remained in good general condition.

PubMed CentralRead more →

Extensive-stage small cell lung cancer: multi-line treatment complicated by glucocorticoid-refractory immune-related cystitis

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported for SCLC. Bladder biopsy during cystitis showed mostly CD3/CD8-positive T-cell inflammation.

As of December 2025, the cancer had progressed through multiple systemic lines, new brain metastasis had appeared, and care had shifted to palliative symptomatic treatment; immune-related cystitis had resolved after prednisone plus mycophenolate mofetil.

PubMed CentralRead more →

Stage IV PD-L1-high lung adenocarcinoma: remission on chemotherapy after tislelizumab-associated KLHL11-IgG cerebellitis

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-high lung adenocarcinoma with EGFR/ALK/ROS1 wild type and TTF-1 positive. KLHL11-IgG was linked to cerebellitis.

Metastatic Site: M1a disease; specific metastatic site not otherwise…

At 1-year neurologic follow-up, the cerebellitis had markedly improved, serum KLHL11-IgG was negative, brain MRI lesions had resolved, and lung adenocarcinoma remained in remission on cisplatin plus pemetrexed.

PubMed CentralRead more →

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Kim's Survivor Story

Patient Info: Kim Rumpf, Female

Biomarkers: ER-negative; PR-negative; HER2-negative

As of June 2026, Kim Rumpf was a triple-negative breast cancer survivor sharing her experience with chemotherapy, double mastectomy, reconstruction, fertility challenges, and advocacy.

Stage IV Colorectal Cancer: Jackie's Patient Story

Patient Info: Jackie, Female | Stage IV

Biomarkers: Lynch syndrome

Metastatic Site: Not reported

Jackie’s Stage IIIB rectal cancer later recurred as Stage IV/metastatic disease, but early immunotherapy response was strong, with no visible tumor on MD Anderson sigmoid scope about 6 weeks after starting treatment.

The Patient StoryRead more →